- Home
- MRNA vs CAI Comparison
MRNA vs CAI Comparison
Compare MRNA & CAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- CAI
- Stock Information
- Founded
- MRNA 2010
- CAI 2008
- Country
- MRNA United States
- CAI United States
- Employees
- MRNA N/A
- CAI N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- CAI Medical Specialities
- Sector
- MRNA Health Care
- CAI Health Care
- Exchange
- MRNA Nasdaq
- CAI Nasdaq
- Market Cap
- MRNA 9.8B
- CAI 8.5B
- IPO Year
- MRNA 2018
- CAI 2025
- Fundamental
- Price
- MRNA $27.89
- CAI $32.98
- Analyst Decision
- MRNA Hold
- CAI Strong Buy
- Analyst Count
- MRNA 17
- CAI 6
- Target Price
- MRNA $42.40
- CAI $35.50
- AVG Volume (30 Days)
- MRNA 12.3M
- CAI 801.5K
- Earning Date
- MRNA 11-06-2025
- CAI 11-12-2025
- Dividend Yield
- MRNA N/A
- CAI N/A
- EPS Growth
- MRNA N/A
- CAI N/A
- EPS
- MRNA N/A
- CAI N/A
- Revenue
- MRNA $3,078,000,000.00
- CAI $533,847,000.00
- Revenue This Year
- MRNA N/A
- CAI $64.66
- Revenue Next Year
- MRNA $9.75
- CAI $45.81
- P/E Ratio
- MRNA N/A
- CAI N/A
- Revenue Growth
- MRNA N/A
- CAI 106.53
- 52 Week Low
- MRNA $23.15
- CAI $25.40
- 52 Week High
- MRNA $59.73
- CAI $42.50
- Technical
- Relative Strength Index (RSI)
- MRNA 58.77
- CAI N/A
- Support Level
- MRNA $26.91
- CAI N/A
- Resistance Level
- MRNA $28.99
- CAI N/A
- Average True Range (ATR)
- MRNA 1.22
- CAI 0.00
- MACD
- MRNA 0.35
- CAI 0.00
- Stochastic Oscillator
- MRNA 76.78
- CAI 0.00
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About CAI Caris Life Sciences Inc. Common Stock
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.